Despite Shenyang Xingqi's lackluster revenue growth, the hig...
Despite Shenyang Xingqi's lackluster revenue growth, the high P/S ratio implies investors are holding stocks in anticipation of a major revenue rebound. Yet, the expected revenue growth that matches with the industry's might not uphold this high P/S in the long run. An uplift in performance is necessary to justify this current ratio.
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Shares May Have Run Too Fast Too Soon
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment